Jan Blankensteijn (Amsterdam, The Netherlands; principal investigator of the DREAM trial) tells Vascular News about what inspired him to design the DREAM trial, how its findings became particularly important with the long-term follow-up data for endovascular aneurysm repair (EVAR) and the current challenges encountered when undertaking randomised trials.
